← Back to Screener

Fielmann

FIE.DE Mid Cap

Healthcare · Medical Instruments & Supplies

Updated: Apr 5, 2026, 17:43 UTC

€43.20
-1.26% today
52W: €38.25 – €58.70
52W Low: €38.25 Position: 24.2% 52W High: €58.70

Key Metrics

P/E Ratio
19.91x
Price-to-Earnings
Forward P/E
16.13x
Forward Price/Earnings
P/S Ratio
1.5x
Price-to-Sales
EV/EBITDA
9.9x
Enterprise Value/EBITDA
Div. Yield
324%
Annual dividend yield
Market Cap
$3.6B
Market Capitalization
Revenue Growth
2.7%
YoY Revenue Growth
Profit Margin
7.55%
Net profit margin
ROE
Return on Equity
Beta
0.63
Market sensitivity
Short Interest
% of float sold short
Avg. Volume
93,867
Average daily volume

Valuation Analysis

Signal
Fair
vs. S&P 500 avg P/E (24.7x)
Analyst Consensus
None
8 analysts
Avg. Price Target
€61.25
+41.78% upside
Target Range
€53.00 – €71.00

About the Company

Fielmann Group AG engages in vision care and audiology business in Germany, Switzerland, Austria, Spain, North America, and internationally. The company manufactures and sells visual aids mainly glasses, eyewear frames and lenses, sunglasses, contact lenses, accessories, hearing systems and its accessories, as well as personal protective equipment. It offers its products under the fielmann, Optika Clarus, Optica & Audiologia Universitaria, Medical optica audicion, Shopko Optical, and SVS VISION brand names. The company sells its products through digital sales, retail stores, as well as Befitting, an optical e-commerce platform. The company was formerly known as Fielmann Aktiengesellschaft and changed its name to Fielmann Group AG in July 2023. Fielmann Group AG was founded in 1972 and is h

Sector: Healthcare Industry: Medical Instruments & Supplies Country: Germany Employees: 20,221 Exchange: GER

Trading Data

50-Day MA: €43.16
200-Day MA: €47.97
Volume: 74,921
Avg. Volume: 93,867
Short Ratio:
P/B Ratio: 3.76x
Debt/Equity: 56.78x
Free Cash Flow:

💵 Dividend Info

Dividend Yield
324%
Annual Rate
€1.40
Payout Ratio
53%

Where can I buy Fielmann?

Compare top-rated brokers — low fees, trusted providers, fully regulated.

Scroll to Top